top of page
搜尋

FDA approves Regeneron's Livsayis as first quarterly siRNA treatment for generalised myasthenia gravis

作家相片: nuaxia
nuaxia
1天前
讀畢需時 1 分鐘

Regeneron's first approved siRNA medicine introduces three-monthly subcutaneous treatment for eligible adults with generalised myasthenia gravis, supported by positive Phase III NIMBLE results.


The US Food and Drug Administration approved Regeneron's Livsayis (cemdisiran) on 18 November 2026 for adults with anti-acetylcholine receptor antibody-positive generalised myasthenia gravis, establishing a complement C5-directed siRNA treatment administered subcutaneously every three months.


In the Phase III NIMBLE study, Livsayis achieved a placebo-adjusted 2.3-point improvement in Myasthenia Gravis Activities of Daily Living score at week 24 (p=0.0005), with 76.6% of treated patients achieving an improvement of at least three points compared with 44.1% receiving placebo; the approval is separate from the previously reported Klygefa authorisation.

Field

Content

Company

Regeneron Pharmaceuticals

Medicine

Livsayis (cemdisiran)

Regulatory Authority

US Food and Drug Administration

Approval Date

18 November 2026

Approval Type

New medicine approval

Therapeutic Area

Neurology and autoimmune neuromuscular disease

Indication

Anti-acetylcholine receptor antibody-positive generalised myasthenia gravis

Eligible Population

Adults with AChR antibody-positive generalised myasthenia gravis

Drug Modality

Small interfering RNA (siRNA)

Molecular Target

Complement component C5

Administration

Subcutaneous injection every three months

Supporting Trial

Phase III NIMBLE

Primary Efficacy Finding

Placebo-adjusted 2.3-point improvement in MG-ADL score at week 24; p=0.0005

Clinically Meaningful Improvement

76.6% achieved at least a three-point MG-ADL improvement versus 44.1% with placebo

Company Milestone

Regeneron's first approved siRNA and neurology medicine

Regulatory Significance

First quarterly siRNA treatment approved for the specified generalised myasthenia gravis population; distinct from Klygefa

Primary Source

https://newsroom.regeneron.com/news-releases/news-release-details/livsayistm-cemdisiran-approved-fda-first-and-only-sirna-therapy


Discover how nuaxia can support your next medical education initiative:

 
 
 

留言

評等為 0(最高為 5 顆星)。
暫無評等

新增評等
bottom of page